An ascending multiple dose study of the safety, pharmacokinetics, and pharmacodynamics of SCA-136 [vabicaserin] administered orally to healthy Japanese male subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2008
At a glance
- Drugs Vabicaserin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Wyeth
- 23 Jan 2008 The expected completion date for this trial is now 1 Oct 2007.
- 04 Dec 2007 Status changed from recruiting to completed.
- 18 Aug 2007 New trial record.